Indian Express

Express India

Screen

Loksatta

Express Cricket

Kashmir Live

Biz Publications
 
| Make this your homepage | Feedback

ANU LABORATORIES

Wait for the healing power

Rajesh Naidu

Posted: May 11, 2008 at 2314 hrs IST
Updated: May 11, 2008 at 2314 hrs IST

Anu Laboratories is engaged in the manufacturing of basic, advanced intermediates and fine chemicals. The main products of the company include 2,4-Di-Chloro-5-Fluoro Acetophenone (DCFA), chlorohexanone, methyl-4 (4-Chloro 1 oxo butane) a Di-Methyl Acetate, and Poly Aluminium Chloride. It supplies these products to various drug manufacturers, which includes Dr Reddy’s Laboratories. Dr Reddy’s Laboratories accounted for around 47.75% of the company’s revenues during 2006-07. The Hyderabad-based company has a facility at Chilkamarri Village, Mehboobnagar.

Apart from Dr Reddy’s Laboratories, the company caters to Nicholas Piramal, Sun Pharmaceuticals, and Divi’s Laboratories and as regards overseas, the company caters to M/s Teva, Mitsui & Co, Sanofi Aventis, Tradecom Services PTE Limited, and Tanabe. The company exports its products to Israel, Italy, Japan, France, the US, and Singapore. At present its exports comprise 12.37% of the total turnover

Objectives of the issue

The company intends to set up a plant for manufacturing of drug intermediates, including Active Pharmaceutical Ingredients (APIs).

For this, the company plans to use Rs 55 crore of around of the Rs 80-crore issue size, considering the higher end of the price band. It plans to set up a pilot plant for carrying out Contract Research and Manufacturing (CRAM). For this, the company has earmarked Rs 8 crore of the total issue. In order to meet its long-term working capital requirement, it has plans to utilise Rs 16 crore.

Investonomics & valuation

On the operational front, the company has demonstrated a growth in operating profit margin in the region of 9-10%. However, stability and sustainability of the margin would be a key thing that investors need to keep a tab of. So is the case with its NPM. After few quarters, it would be clearer as to whether the company manages sustainable growth.

On the valuation front, the company quotes a P/E of around 18(x) and 19(x) at the lower and higher end of the price band respectively. Its peers like SMS Pharmaceuticals (sales-Rs 175 crore, PAT-Rs 21 crore) and Dishman Pharma (annualised sales-Rs 133 crore, annualised PAT-Rs 28 crore), quote a P/E of around 8.9(x) and 21(x) respectively. It must be noted that these are bigger companies

The company does not have long-term contracts with customers and typically operates on the basis of purchase orders. At present, it doesn’t have any formal arrangement for supply of any of its products, except for Ciprofloxacin Hcl, for which they have entered into formal...

Single Page Format 1 - 2 - Next
Ads by Google
Discuss this story on expressindia forums

Post Comments

Comments: (Limit 3,000 characters)
Name
Message
Email ID
Subject
TERMS OF USE:
The views represented here are not endorsed by www.financialexpress.com. The person writing and submitting the comment is / are responsible for the content of comment. The comment should not have inflammatory, abusive, derogatory language or any language deemed unfit for publication. There will be time lag between the submission and publication of the comments. The website reserves the right to publish or reject any message.
I agree to the terms of use.

Comments
Shaadi Matrimonials
Get Marriage Proposals by Email EVERYDAY!
Register FREE on Naukri.com.
200000+ Hot Job Openings!
The smartest way
to call india
Hot Travel Deals
- Yatra.com
Send Gifts
Flowers and Gifts
Get talk time of 200 minutes
absolutely free